ABCL · Company research
AbCellera Biologics Inc. Common Shares (ABCL): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates | Nurix Therapeutics reported Q3 2026 earnings of $4.73 per share, significantly beating the consensus estimate of a loss of $0.56 per share, with a 944.64% earnings surprise. Revenues reached $673.06 million, surpassing estimates by 383.11%. However, the stock received a Zacks Rank #3 (Hold) rating, with mixed estimate revisions and the company's industry ranking in the bottom 33% of sectors. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bearish | -0.5 | 1 |
| Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera | The global synthetic antibody library market is projected to grow from $1.63 billion in 2025 to $2.86 billion by 2030, representing a 12% CAGR. Growth is driven by AI-integrated antibody design, increased demand for therapeutic antibodies, high-throughput screening technologies, and expansion of contract research organizations. North America leads the market while Asia-Pacific shows fastest growth potential. | View source ↗ | GlobeNewswire Inc. | Oct 12, 2026 | bullish | 1 | 1 |
| AbCellera Biologics (NasdaqGS:ABCL) Stock Forecast & Analyst Predictions - Simply Wall Street | AbCellera Biologics (NasdaqGS:ABCL) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 12, 2026 | neutral | 0 | 0.6 |
| AbCellera Biologics Inc. (8QQ.F) Stock Price, News, Quote & History - Yahoo! Finance Canada | AbCellera Biologics Inc. (8QQ.F) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 11, 2026 | neutral | 0 | 0.6 |
| AbCellera Biologics Inc. (ABCL) Stock Price, News, Quote & History - Yahoo! Finance Canada | AbCellera Biologics Inc. (ABCL) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 8, 2026 | neutral | 0 | 0.6 |
| AbCellera (ABCL) to Present Phase 1/2 Trial Data for ABCL635 at Upcoming Menopause Society Meeting - GuruFocus | AbCellera (ABCL) to Present Phase 1/2 Trial Data for ABCL635 at Upcoming Menopause Society Meeting GuruFocus | View source ↗ | GuruFocus | Oct 8, 2026 | neutral | 0 | 0.6 |
| AbCellera Biologics (Nasdaq:ABCL) - Stock Analysis - Simply Wall Street | AbCellera Biologics (Nasdaq:ABCL) - Stock Analysis Simply Wall Street | View source ↗ | Simply Wall Street | Oct 6, 2026 | neutral | 0 | 0.6 |
| At 3 p.m. Pacific Time on Nov. 9, AbCellera will hold its third-quarter results call. - Stock Titan | At 3 p.m. Pacific Time on Nov. 9, AbCellera will hold its third-quarter results call. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Should I Buy ABCL? ABCL 2026 Analysis - Intellectia AI™ - Intellectia AI | Should I Buy ABCL? ABCL 2026 Analysis - Intellectia AI™ Intellectia AI | View source ↗ | Intellectia AI | Sep 26, 2026 | neutral | 0 | 0.6 |
| Is AbCellera Biologics (ABCL) Undervalued On Its ABCL635 Phase 2 Data Presentation? - Simply Wall Street | Is AbCellera Biologics (ABCL) Undervalued On Its ABCL635 Phase 2 Data Presentation? Simply Wall Street | View source ↗ | Simply Wall Street | Sep 26, 2026 | neutral | 0 | 0.6 |
| ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know - Yahoo Finance | ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know Yahoo Finance | View source ↗ | Yahoo Finance | Sep 22, 2026 | neutral | 0 | 0.6 |
| AbCellera Biologics Stock (ABCL) Opinions on Recent Surge and Insider Buying - Quiver Quantitative | AbCellera Biologics Stock (ABCL) Opinions on Recent Surge and Insider Buying Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 26, 2026 | neutral | 0 | 0.6 |
| AbCellera Biologics Stock (ABCL) Opinions on Recent Surge and Insider Buying - Quiver Quantitative | AbCellera Biologics Stock (ABCL) Opinions on Recent Surge and Insider Buying Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 26, 2026 | neutral | 0 | 0.6 |
| AbCellera Biologics Stock (ABCL) Opinions on Positive Phase 2 Trial Results - Quiver Quantitative | AbCellera Biologics Stock (ABCL) Opinions on Positive Phase 2 Trial Results Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 15, 2026 | neutral | 0 | 0.6 |
| 6 Green Days In A Row: AbCellera Biologics Stock Is Up 85% - Trefis | 6 Green Days In A Row: AbCellera Biologics Stock Is Up 85% Trefis | View source ↗ | Trefis | Aug 14, 2026 | neutral | 0 | 0.6 |
| AbCellera Biologics Stock 6-Day Winning Spree: Stock Climbs 85% - Trefis | AbCellera Biologics Stock 6-Day Winning Spree: Stock Climbs 85% Trefis | View source ↗ | Trefis | Aug 14, 2026 | neutral | 0 | 0.6 |
| AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal - Yahoo Finance | AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal Yahoo Finance | View source ↗ | Yahoo Finance | Aug 11, 2026 | neutral | 0 | 0.6 |
| ABCL Stock On Track For Best Day In Nearly 4.5 Years After Positive Phase 2 Menopause Drug Data - Yahoo Finance | ABCL Stock On Track For Best Day In Nearly 4.5 Years After Positive Phase 2 Menopause Drug Data Yahoo Finance | View source ↗ | Yahoo Finance | Aug 10, 2026 | neutral | 0 | 0.6 |
| ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost - Stocktwits | ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost Stocktwits | View source ↗ | Stocktwits | May 8, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.